Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

An ivonescimab-chemotherapy combination succeeded in a study in China. Elsewhere, the FDA asked Novavax for more COVID ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

Henry Gosebruch is now chief executive of the spinout, which has roughly $2.5 billion and plans to use dealmaking to build a ...

The law in particular will affect CVS and UnitedHealth, both of which operate physical pharmacies in the state along with ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing ...

The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the ...

Alis Biosciences says its goal is to return to investors billions of dollars stuck on the balance sheets of “moribund” ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

Commissioner Martin Makary said the agency would, whenever possible, restrict drug company employees from participating as ...

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about ...